SANGUINE CORP. (SGNC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: UnderCover	5/16/2005 2:06:23 PM
	Read Replies (1) of 5402

For many years a huge amount of interest has been shown in perfluorocarbons for medical applications due to their remarkably low toxicity, lack of biological activity, short retention time in the body and their ability to dissolve gases especially oxygen and carbon dioxide. Blood Extenders (Substitutes) For many years there has been interest in using perfluorocarbons to minimise the risk of allogeneic blood transfusions. Perfluorocarbons are immisible with blood so they are used in an emulsion form. The first emulsions were developed by the Green Cross Company in Japan in the mid 1970's, new emulsions in development have enhanced oxygen carrying capacity, better emulsion stability, and no associated hemodynamic effects on administration. Perfluorocarbons emulsions have a relatively small particle size and so have the added advantage that they are able to oxygenate ischaemic tissue and tumours (increasing sensitivity to radiation therapy). Typical compound used : Perfluorodecalin ( I assume sanguines product is similar or adaptable). Further Reading: ML Nucci, A Abuchowshi, Sci. Amer, Feb 1998, 61-65

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next